Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: A double-blind, placebo-controlled study

Clinical Therapeutics

Volumn 27, Issue 9, 2005, Pages 1403-1410

  Taekema Roelvink, Miriam E J ^a   Swart, Piet J ^a   Kuipers, Mirjam E ^a   Krauwinkel, Walter J J ^a   Visser, Nico ^a   Smulders, Ronald A ^a  

^a Astellas Pharma Global Development   (Netherlands)

Author keywords

Ethinyl estradiol; Levonorgestrel; Muscarinic receptor antagonist; Oral contraceptive; Pharmacokinetics; Solifenacin succinate

Indexed keywords

ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FOLLITROPIN; LEVONORGESTREL; LUTEINIZING HORMONE; PLACEBO; SOLIFENACIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIRTH DEFECT; BLOOD SAMPLING; BODY HEIGHT; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; COMPARATIVE STUDY; CONGENITAL MALFORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISABILITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FATIGUE; FEMALE; HEADACHE; HUMAN; LABORATORY TEST; ORAL CONTRACEPTION; PHARMACOLOGICAL PARAMETERS; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SMOKING; STATISTICAL ANALYSIS; XEROSTOMIA;

ADULT; AREA UNDER CURVE; CONTRACEPTIVES, ORAL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ETHINYL ESTRADIOL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LEVONORGESTREL; LUTEINIZING HORMONE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; QUINUCLIDINES; TETRAHYDROISOQUINOLINES;

EID: 27744570435     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.09.002     Document Type: Article

References (13)

1. Rovner ES, and Wein AJ Incidence and prevalence of overactive bladder Curr Urol Rep 3 2002 434 438
2. (Suppl) Milsom I, Stewart W, and Thuroff J The prevalence of overactive bladder Am J Manag Care 6 2000 S565 S573
3. for the Standardisation Sub-committee of the International Continence Society Abrams P, Cardozo L, and Fall M The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society Neurourol Urodyn 21 2002 167 178
4. Heinemann K, Moehner S, and Lewis M Trends of OC use 1980-1999 in a German cohort of women [in German] Zentralbl Gynakol 124 2002 128 131
5. Wein AJ, and Rovner ES The overactive bladder: An overview for primary care health providers Int J Fertil Womens Med 44 1999 56 66
6. Krauwinkel WJ, Smulders RA, and Mulder H Effect of age on the pharmacokinetics of solifenacin in men and women Int J Clin Pharmacol Ther 43 2005 227 238
7. Smulders RA, Krauwinkel WJ, Swart PJ, and Huang M Pharmacokinetics and safety of solifenacin succinate in healthy young men J Clin Pharmacol 44 2004 1023 1033
8. [published correction appears in BUJ Int. 2004;93:1135] Chapple CR, Arano P, and Bosch JL Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study BJU Int 93 2004 71 77
9. Available at The European Agency for the Evaluation of Medicinal Products ICH Topic E 6: Guideline for Good Clinical Practice Accessed August 24 2005
10. Yamazaki H, and Shimada T Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes Arch Biochem Biophys 346 1997 161 169
11. Yamazaki H, Shaw PM, Guengerich FP, and Shimada T Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes Chem Res Toxicol 11 1998 659 665
12. for the Council on Scientific Affairs, American Medical Association Dickinson BD, Altman RD, Nielsen NH, and Sterling ML Drug interactions between oral contraceptives and antibiotics Obstet Gynecol 98 2001 853 860
13. Hemrika DJ, Slaats EH, and Kennedy JC Pulsatile luteinizing hormone patterns in long term oral contraceptive users J Clin Endocrinol Metab 77 1993 420 426